CAMP (CAMP4 Therapeutics Corporation) Stock Financials & Earnings | Market Cap Arena

CAMP (CAMP4 Therapeutics Corporation) Stock Financials & Earnings | Market Cap Arena

CAMPCAMP4 Therapeutics Corporation

Mkt Cap$125M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$3M

Net Income (TTM)-$80M

EPS (TTM)-$2.59

Free Cash Flow (TTM)-$30M

Gross Margin77.5%

Op. Margin-1488.3%

Net Margin-2298.5%

FCF Margin-852.8%

P/S Ratio (TTM)35.9x

P/E Ratio (TTM)—

YoY Rev Growth+436.5%

Employees—

Earnings Reports

Next: Q1 2026 · Mar 26

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$79M	$28M	-$2M
Q2 23	$71M	$27M	-$3M
Q3 23	$350K	$350K	-$12M
Q4 23	$0	$0	-$13M
Q1 24	$0	$0	-$13M
Q2 24	$0	$0	-$13M
Q3 24	$0	$0	-$14M
Q4 24	$652K	$652K	-$14M
Q1 25	$858K	$858K	-$13M
Q2 25	$1M	$1M	-$13M
Q3 25	$795K	$379K	-$13M
Q4 25	$348K	-$24K	-$13M

Valuation

Quarter	P/S	P/E
Q1 23	0.4x	—
Q2 23	0.4x	—
Q3 23	0.5x	—
Q4 23	0.8x	—
Q1 24	1.8x	—
Q2 24	358.4x	—
Q3 24	—	—
Q4 24	192.4x	—
Q1 25	83.1x	—
Q2 25	41.7x	—
Q3 25	33.0x	—
Q4 25	35.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$1M	-$1M
Q2 23	-$3M	-$3M
Q3 23	-$7M	-$7M
Q4 23	-$12M	-$12M
Q1 24	-$11M	-$11M
Q2 24	-$13M	-$14M
Q3 24	-$10M	-$10M
Q4 24	-$11M	-$12M
Q1 25	-$14M	-$15M
Q2 25	-$10M	-$10M
Q3 25	-$11M	-$11M
Q4 25	$6M	$6M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$114K
Q2 23	$114K
Q3 23	$207K
Q4 23	$243K
Q1 24	$15K
Q2 24	$163K
Q3 24	$0
Q4 24	$263K
Q1 25	$279K
Q2 25	$0
Q3 25	$0
Q4 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+14.8%	+10.0%
Q2 23	+9.5%	-0.9%
Q3 23	-99.5%	-83.8%
Q4 23	-100.0%	-83.7%
Q1 24	-100.0%	-83.9%
Q2 24	-100.0%	-82.7%
Q3 24	-100.0%	+6.5%
Q4 24	—	+9.0%
Q1 25	—	+8.4%
Q2 25	—	+14.7%
Q3 25	—	+3.2%
Q4 25	-46.6%	-10.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$775K	1.0%
Q2 23	$775K	1.1%
Q3 23	$722K	206.3%
Q4 23	$636K	—
Q1 24	$856K	—
Q2 24	$786K	—
Q3 24	$2M	—
Q4 24	$797K	122.2%
Q1 25	$861K	100.3%
Q2 25	$1M	66.9%
Q3 25	$984K	123.8%
Q4 25	$1M	330.7%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$5M	$12M	$11M	—
Q2 23	$6M	$11M	$11M	—
Q3 23	$10M	$3M	—	—
Q4 23	$11M	$3M	—	—
Q1 24	$10M	$3M	—	—
Q2 24	$9M	$3M	—	—
Q3 24	$10M	$4M	—	—
Q4 24	$10M	$5M	—	—
Q1 25	$10M	$4M	—	—
Q2 25	$10M	$4M	—	—
Q3 25	$9M	$5M	—	—
Q4 25	$8M	—	—	$5M

Revenue Segments

Quarter	Application Subscriptions And Other Services	Product
Q1 23	$28M	$50M
Q2 23	$25M	$46M
Q4 23	$22M	$31M

Revenue by Geography

Quarter	All Other	Asia Pacific	E M E A	Latin America	United States	Emea
Q2 23	$1M	$6M	$17M	$7M	$39M	—
Q4 23	$2M	$5M	—	$4M	$29M	$14M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$42M	$0	$42M
Q2 23	$35M	$0	$35M
Q3 23	$39M	$0	$39M
Q4 23	$38M	$0	$38M
Q1 24	$13M	$0	$13M
Q2 24	$13M	$0	$13M
Q3 24	$3M	$0	$3M
Q4 24	$64M	$0	$64M
Q1 25	$49M	$0	$49M
Q2 25	$39M	$0	$39M
Q3 25	$75M	$0	$75M
Q4 25	$110M	$0	$110M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	36M	-0.6%
Q2 23	37M	+1.4%
Q3 23	37M	+1.0%
Q4 23	37M	+1.2%
Q1 24	12M	-67.6%
Q2 24	16M	+30.4%
Q3 24	20M	+23.3%
Q4 24	20M	+0.0%
Q1 25	20M	+0.0%
Q2 25	20M	+3.4%
Q3 25	20M	+0.0%
Q4 25	52M	+157.5%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	—	—
FY 16	—	—
FY 17	—	—
FY 18	—	—
FY 19	—	—
FY 20	—	—
FY 21	—	—
FY 22	—	—
FY 23	—	—
FY 24	$65	10K
FY 25	$167	21K